Visual Acuity Terminated Phase 3 Trials for Infliximab (DB00065)

IndicationStatusPhase
DBCOND0035258 (Visual Acuity)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00505947Treatment of Refractory Diabetic Macular Edema With InfliximabTreatment